|
Gilead and Kite Onology
launch CAR T-Cell therapy
operations in Brazil,
Singapore, and Saudi Arabia
(Saudi Arabia) -
Gilead Sciences in
Saudi Arabia has announced
that Gilead and
Kite
Oncology is expanding its
business with the launch of
operations in Brazil, Saudi
Arabia and Singapore. Gilead
has submitted regulatory
applications for Kite’s CAR
T-cell therapy products in
all three countries.
Advanced blood cancers
represent an area of
significant need across all
three countries. In both
Singapore and Saudi Arabia,
lymphomas are the fifth most
common cancer overall; more
than 1,000 new cases of
non-Hodgkin lymphoma (NHL)
are diagnosed in Singapore
and nearly 1,700 in Saudi
Arabia each year. In
Brazil, more than 12,000
cases of NHL are estimated
to be diagnosed per year.
"As
the global cell therapy
leader, Kite is working to
bring access to CAR T-cell
therapy to new areas around
the world where patients
currently do not have access
to this potential cure for
some advanced blood
cancers,” said Christi Shaw,
Chief Executive Officer of
Kite. “We are pleased to
continue expanding our
international operations and
look forward to partnering
with the health care systems
in these regions.”
Dedicated Gilead and Kite
teams are now in place
working to qualify leading
hospitals to administer CAR
T-cell therapy in each of
the new countries, pending
local regulatory approvals,
and the Company plans to
increase its workforce in
these countries in 2022.
Gilead and Kite currently
has more than 300 qualified
treatment centers globally,
including in the U.S.,
Australia, Canada and
Europe, as well as through
our joint venture in China
and our licensing partner in
Japan.
Currently,
Kite is the only company
dedicated exclusively to the
research, development, and
manufacturing of cell
therapy on a global scale.
Kite is unique in that all
functions dedicated to cell
therapy are vertically
integrated under one
leadership team for
efficient delivery of the
highly specialized and
complex end-to-end processes
needed to support CAR T-cell
therapy.
References:
1) Lymphoma incidence in
Saudi Arabia. 2020 Factsheet
Saudi Arabia. Available at:
https://gco.iarc.fr/today/data/factsheets/populations/682-saudi-arabia-fact-sheets.pdf.
2)
International Agency for
Research on Cancer. Globocan
2020 Singapore. Available
at:
https://gco.iarc.fr/today/data/factsheets/populations/702-singapore-fact-sheets.pdf.
3)
Instituto Nacional de Câncer
(INCA). Tipos de câncer,
Linfoma não Hodgkin.
Available at:
https://www.gov.br/inca/pt-br/assuntos/cancer/tipos/linfoma-nao-hodgkin.
PRINT
THIS ARTICLE
|